Drug Profile

Rifabutin

Alternative Names: Ansamycin; Ansatipin; Ansatipine; LM 427; Mycobutin

Latest Information Update: 23 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pfizer
Class Anti-infectives; Antibacterials; Antituberculars; Aza compounds; Ethers; Piperidines; Rifamycins; Small molecules; Spiro compounds
Mechanism of Action Protein 50S ribosomal subunit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Mycobacterium avium complex infections

Most Recent Events

21 Dec 2021 Rifabutin Capsules USP approved in USA for Mycobacterium avium complex infections
01 Feb 2015 Pfizer and Ottawa Hospital Research Institute completes a phase I trial in healthy volunteers in Canada (NCT01894776)
07 Oct 2009 Launched for Mycobacterium avium complex infections in European Union (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com